Oncotarget

Research Papers:

Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer

Shanshan Wu, Xiangfei Zhao, Sudong Wu, Rui Du, Qi Zhu, Henghu Fang, Xinhong Zhang, Chunyang Zhang, Wei Zheng, Jihua Yang and Huasong Feng _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:81750-81756. https://doi.org/10.18632/oncotarget.13177

Metrics: PDF 2080 views  |   HTML 2843 views  |   ?  


Abstract

Shanshan Wu1,2,*, Xiangfei Zhao2,*, Sudong Wu2, Rui Du2, Qi Zhu2, Henghu Fang2, Xinhong Zhang2, Chunyang Zhang2, Wei Zheng2, Jihua Yang2, Huasong Feng2

1Postgraduate Team, Chinese PLA General Hospital, Beijing 100853, China

2Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China

*These authors have contributed equally to this work

Correspondence to:

Huasong Feng, email: [email protected]

Keywords: meta-analysis, B7-H3, prognosis, lung cancer, clinical

Received: September 08, 2016     Accepted: October 19, 2016     Published: November 07, 2016

ABSTRACT

Previous studies have investigated the prognostic significance of B7 homolog 3 (B7-H3) in non-small cell lung cancer (NSCLC), however, the results remain controversial. This study was aimed to determine the correlation between B7-H3 and survival as well as clnicalpathological characteristics in NSCLC using meta-analysis. We searched the electronic databases of PubMed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI) for relevant studies up to October 9, 2016. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to estimate the impact of B7-H3 on overall survival (OS). Combined odds ratios (ORs) and 95%CIs were utilized to evaluate the correlations between B7-H3 and clinicalpathological features. This meta-analysis finally included 7 studies with 864 patients. The results showed that B7-H3 had no significant association with OS (HR=0.88, 95%CI: 0.36-2.13, p=0.776). High B7-H3 expression was a significant indicator of lymph node metastasis (OR=3.92, 95%CI: 2.65-5.81, p<0.001), and advanced TNM stage (OR=3.53, 95%CI: 2.45-5.09, p<0.001). B7-H3 has the potential to serve as a marker of tumor aggressiveness and lymph node metastasis in NSCLC. However, due to several limitations, further large-scale studies are needed to validate our results.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13177